Helicobacter Pylori Infections Market is Projected to Grow by 2034

DelveInsight’s latest publication, “Helicobacter Pylori Infections Market Insights, Epidemiology, and Market Forecast – 2034” reveals substantial growth opportunities within the global Helicobacter pylori (H. pylori) infections market. In 2022, the Helicobacter pylori (H. pylori) infections market size across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan was valued at approximately USD 2,672.5 million and is expected to exhibit steady expansion through 2034. The increasing prevalence of H. pylori infection, heightened focus on early diagnosis, and the introduction of innovative therapies are the primary forces driving market growth.

United States Leads the 7MM Market With USD 1,064.8 Million Share in 2022

Within the 7MM, the United States represented the largest Helicobacter pylori (H. pylori) infections market, accounting for roughly USD 1,064.8 million in revenue in 2022. The strong U.S. market position is attributed to improved awareness, advancements in diagnostic technologies, and the adoption of recently approved treatment regimens. The resurgence of interest in overcoming rising antimicrobial resistance is also playing a central role in shaping future drug development strategies.

Clarithromycin-based triple therapy comprising a proton pump inhibitor (PPI), clarithromycin, and either amoxicillin or metronidazole - remains the gold-standard therapy and generated USD 351 million in U.S. revenue during 2022. While this regimen continues to be widely used, escalating antibiotic resistance rates have created an urgent need for more effective and resistance-resilient treatment combinations.

Evolving Treatment Landscape: Growing Adoption of Novel and Re-launched Therapies

The treatment ecosystem is currently undergoing a dynamic transformation. Traditional therapies such as PREVPAC, PYLERA, and numerous generics have long dominated the market. These therapies aim to eradicate Helicobacter pylori (H. pylori) infections, support gastric ulcer healing, and lower recurrence rates. However, newly approved and strategically reintroduced drugs are accelerating competition.

Significant therapies reshaping the market include:

• TALICIA (RedHill Biopharma) – A rifabutin-based triple therapy designed to target antibiotic-resistant strains
• VOQUEZNA Triple and Dual Packs (Phathom Pharmaceuticals) – Approved in 2022 and relaunched in 2023, featuring vonoprazan, a potassium-competitive acid blocker (P-CAB) with superior acid suppression properties

These advancements are providing clinicians with additional tools to manage both first-line and treatment-resistant infections.

Strong Pipeline Poised to Drive the Next Wave of Helicobacter pylori (H. pylori) infections Market Growth

The H. pylori infections pipeline remains active, with several companies pursuing innovative therapeutic candidates aimed at improving eradication outcomes, minimizing resistance, and enhancing patient compliance.

Among various emerging therapies, TenNor Therapeutics’ Rifasutenizole (TNP-2198) is widely viewed as a potential game-changer. This dual-mechanism agent is anticipated to launch in 2027 and is specifically engineered to combat antimicrobial resistance - one of the core challenges in current treatment strategies.

Other key companies actively developing H. pylori therapeutics include:

Servatus Biopharmaceuticals, Cinclus Pharma, Crestone, EpiVax, Iguana Biotechnology, ImevaX GmbH, ImmunoBiology, Luoxin Pharmaceuticals, Nexbiome Therapeutics, Recce Pharmaceuticals, SCG Cell Therapy, Shanghai High-Tech Bioengineering, Takeda Pharmaceutical, TenNor Therapeutics, Trio Medicines, and Xiamen Encheng Pharmaceutical.

Latest Research and Development Milestones Bolster Helicobacter pylori (H. pylori) infections Market Optimism

The past few years have seen a surge in pivotal clinical developments:

• March 2025: TenNor Therapeutics reported positive Phase 3 results for Rifasutenizol (TNP-2198) combined with rabeprazole and amoxicillin for first-line H. pylori treatment.
• February 2025: Phase 1 study results for TNP-2092 showed promising pharmacokinetic and preliminary efficacy outcomes.
• December 2024: Daewoong Pharmaceutical announced positive Phase III findings for DWP14012-based triple therapy.
• November 2024: TenNor confirmed Rifasutenizol achieved all primary Phase III endpoints, delivering eradication rates exceeding 90% - outperforming standard bismuth-containing quadruple therapy (BQT).
• March 2024: A diagnostic-focused study highlighted the effectiveness of stool antigen testing (SAT) and serum IgG antibody assays in distinguishing acute vs. chronic infections.
• September 2022: The U.S. FDA awarded QIDP designation to linaprazan glurate for H. pylori infection treatment.

Meanwhile, a large-scale Phase III study continues in China to evaluate population-level screening and eradication strategies, marking a significant advancement in preventive interventions for gastric cancer.

Helicobacter pylori (H. pylori) infections Epidemiological Insights: Over 321 Million Diagnosed Cases Across the 7MM in 2022

The epidemiological burden of H. pylori infection remains substantial. In 2022:

• The 7MM registered approximately 321.2 million diagnosed cases
• The United States accounted for ~118.6 million cases, driven by higher screening rates
• EU4 and the UK together reported ~138.4 million cases, with France contributing the largest share
• Japan reported ~64.2 million cases, ranking second globally

The U.S. exhibited a slight male predominance (52%) and the highest prevalence in the population over 40 years old. As screening tools become more accessible and emerging diagnostics such as SAT and molecular assays gain traction, the diagnosed patient pool is projected to expand significantly by 2034.

Helicobacter pylori (H. pylori) infections Market Outlook: Robust Growth Expected Through 2034

According to DelveInsight’s market model:

• The combined EU4 and UK Helicobacter pylori (H. pylori) infections market generated USD 1,028.3 million in 2022, representing about 38% of the total 7MM market
• Japan Helicobacter pylori (H. pylori) infections market contributed USD 579.4 million, maintaining a consistently strong position
• New treatment entrants, better diagnostics, and wider uptake of advanced regimens like TALICIA and VOQUEZNA are expected to fuel strong growth

By therapy, the market comprises a broad mix of PPI-based triple therapies, bismuth quadruple therapies, P-CAB combinations, and emerging targeted antibiotics.

Helicobacter pylori (H. pylori) infections Drugs Uptake and Competitive Landscape

The competitive landscape is diverse, with major current and pipeline therapies including:

• TALICIA (RedHill Biopharma)
• VOQUEZNA Triple & Dual Packs (Phathom Pharmaceuticals)
• TAKECAB / Vonoprazan (Takeda)
• PYLERA (AbbVie/Juvisé)
• Rifasutenizole (TNP-2198) – TenNor Therapeutics
• Linaprazan glurate – Cinclus Pharma
• BGA-1901 – Nexbiome
• SQ109, Tegoprazan, CRS3123, and several more in development

With multiple companies targeting innovative bactericidal and acid-suppressive mechanisms, the competitive intensity is expected to increase markedly into the next decade.

Key Insights From the Helicobacter pylori (H. pylori) Infections Market Report

DelveInsight’s report provides comprehensive coverage of:

• Market size, trends, and therapy segmentation
• Competitive landscape assessment
• Epidemiology and patient population characteristics
• Emerging diagnostic advancements
• Developmental pipeline and drug-level market shares
• Unmet needs and evolving clinical guidelines
• Market drivers, barriers, and opportunity hotspots